712 North is a pre-clinical stage pharmaceutical company based in California. We develop modulators of the dynamic mitochondrial network for a range of age-related diseases such as Alzheimer's, cancer, glaucoma, and cardiovascular disease. The mechanism of action ties the biology also to a rare pediatric indication with unmet medical need. We can leverage this orphan disease as fast to market strategy. Our goal is to become the global leader in innovative personalized mitochondrial medicines.